https://www.prnewswire.com/news-releases/i-mab-biopharma-receives-ind-approval-in-china-for-proprietary-cd73-antibody-tjd5-300931152.html
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
/PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and...
https://www.prnewswire.com/news-releases/i-mab-biopharma-and-junshi-biosciences-announce-collaboration-to-evaluate-tjd5-in-combination-with-toripalimab-for-the-treatment-of-patients-with-cancers-in-china-300914959.html
I-Mab Biopharma and Junshi Biosciences Announce Collaboration to Evaluate TJD5 in Combination with...
/PRNewswire/ -- I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development...